V. , R. De-la-cohorte, .. De, and M. , 47 A Description47 1. Description de la première ligne thérapeutique 47 a) Caractéristiques de la population à l'initiation, 47 b) Caractéristiques du traitement par, p.48

.. Du-lénalidomide, 50 a) Caractéristiques de la population à l'initiation du lénalidomide 50 b) Caractéristiques du traitement par lénalidomide, p.51

C. Impact-de-la-réponse-À-mpt-sur-le-devenir-des-patients-et-leur-réponse-au-lénalidomide and .. , 56 1. Impact sur la survie globale 56 2. Impact sur la survie sans progression, p.57

.. Au-traitement, 61 1. Impact sur la survie globale 61 2. Impact sur la survie sans progression, Lénalidomide en première ou deuxième rechute : impact sur le devenir et la réponse des patients, p.62

F. Gay and A. Palumbo, Management of older patients with multiple myeloma. Blood Rev. 2011 mars, pp.65-73

C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker et al., Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial, Journal of Clinical Oncology, vol.27, issue.22, pp.3664-3670, 2009.
DOI : 10.1200/JCO.2008.21.0948

A. Palumbo and F. Gay, How to treat elderly patients with multiple myeloma: combination of therapy or sequencing, Hematology, vol.2009, issue.1, pp.566-577, 2009.
DOI : 10.1182/asheducation-2009.1.566

C. Hulin, Les nouveaux m??dicaments du??my??lome, La Revue de M??decine Interne, vol.28, issue.10, pp.682-688, 2007.
DOI : 10.1016/j.revmed.2007.04.012

R. Kyle, T. Therneau, S. Rajkumar, J. Offord, D. Larson et al., A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-569, 2002.
DOI : 10.1056/NEJMoa01133202

R. Kyle and S. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, vol.22, issue.1, pp.3-9, 2009.
DOI : 10.1038/leu.2008.291

P. Moreau, C. Hulin, and T. Facon, Frontline treatment of multiple myeloma in elderly patients, Blood Reviews, vol.22, issue.6, pp.303-309, 2008.
DOI : 10.1016/j.blre.2008.04.002

P. Greipp, S. Miguel, J. Durie, B. Crowley, J. Barlogie et al., International Staging System for Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.15, pp.3412-3420, 2005.
DOI : 10.1200/JCO.2005.04.242

R. Bataille, J. Grenier, and J. Sany, Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients, Blood, vol.63, pp.468-476, 1984.

H. Avet-loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban et al., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-3495, 2007.
DOI : 10.1182/blood-2006-08-040410

B. Durie and S. Salmon, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 sept, pp.842-854

H. Avet-loiseau, Role of genetics in prognostication in myeloma, Best Practice & Research Clinical Haematology, vol.20, issue.4, pp.625-635, 2007.
DOI : 10.1016/j.beha.2007.08.005

A. Riccardi, O. Mora, C. Tinelli, D. Valentini, S. Brugnatelli et al., Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study, British Journal of Cancer, vol.82, issue.7, pp.1254-1260, 2000.
DOI : 10.1054/bjoc.1999.1087

M. Attal, J. Harousseau, A. Stoppa, J. Sotto, J. Fuzibet et al., A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, New England Journal of Medicine, vol.335, issue.2, pp.91-97, 1996.
DOI : 10.1056/NEJM199607113350204

R. Alexanian, A. Haut, A. Khan, M. Lane, E. Mckelvey et al., Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens, JAMA: The Journal of the American Medical Association, vol.208, issue.9, pp.1680-1685, 19692.
DOI : 10.1001/jama.208.9.1680

S. Kumar, S. Rajkumar, A. Dispenzieri, M. Lacy, S. Hayman et al., Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2520, 2008.
DOI : 10.1182/blood-2007-10-116129

A. Palumbo, S. Bringhen, T. Caravita, E. Merla, V. Capparella et al., Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial, The Lancet, vol.367, issue.9513, pp.825-831, 2006.
DOI : 10.1016/S0140-6736(06)68338-4

T. Facon, J. Mary, C. Hulin, L. Benboubker, M. Attal et al., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99???06): a randomised trial, The Lancet, vol.370, issue.9594, pp.1209-1218, 2007.
DOI : 10.1016/S0140-6736(07)61537-2

P. Wijermans, M. Schaafsma, F. Termorshuizen, R. Ammerlaan, S. Wittebol et al., Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study, Journal of Clinical Oncology, vol.28, issue.19, pp.3160-3166, 2010.
DOI : 10.1200/JCO.2009.26.1610

A. Waage, P. Gimsing, P. Fayers, N. Abildgaard, L. Ahlberg et al., Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma, Blood, vol.116, issue.9, pp.1405-1412, 20102.
DOI : 10.1182/blood-2009-08-237974

S. Miguel, J. Schlag, R. Khuageva, N. Dimopoulos, M. Shpilberg et al., Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma, New England Journal of Medicine, vol.359, issue.9, pp.906-917, 2008.
DOI : 10.1056/NEJMoa0801479

D. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch et al., Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America, New England Journal of Medicine, vol.357, issue.21, pp.2133-2142, 2007.
DOI : 10.1056/NEJMoa070596

M. Dimopoulos, A. Spencer, M. Attal, H. Prince, J. Harousseau et al., Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma, New England Journal of Medicine, vol.357, issue.21
DOI : 10.1056/NEJMoa070594

S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson et al., Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, New England Journal of Medicine, vol.341, issue.21, pp.1565-1571, 1999.
DOI : 10.1056/NEJM199911183412102

D. Amato, R. Loughnan, M. Flynn, E. Folkman, and J. , Thalidomide is an inhibitor of angiogenesis., Proceedings of the National Academy of Sciences, vol.91, issue.9, pp.4082-4085, 1994.
DOI : 10.1073/pnas.91.9.4082

S. Kumar and S. Rajkumar, Thalidomide and lenalidomide in the treatment of multiple myeloma, European Journal of Cancer, vol.42, issue.11, pp.1612-1622, 2006.
DOI : 10.1016/j.ejca.2006.04.004

A. Glasmacher, C. Hahn, F. Hoffmann, R. Naumann, H. Goldschmidt et al., A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma, British Journal of Haematology, vol.102, issue.2, pp.584-593, 2006.
DOI : 10.1093/annonc/mdh026

A. Palumbo, A. Bertola, P. Musto, T. Caravita, V. Callea et al., Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer, pp.1428-1433, 2005.

M. Beksac, R. Haznedar, T. Firatli?tuglular, H. Ozdogu, I. Aydogdu et al., Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, European Journal of Haematology, vol.112, issue.1, pp.16-22, 2011.
DOI : 10.1111/j.1600-0609.2010.01524.x

P. Fayers, A. Palumbo, C. Hulin, A. Waage, P. Wijermans et al., Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials, Blood, vol.118, issue.5, pp.1239-1247, 2011.
DOI : 10.1182/blood-2011-03-341669

P. Richardson, R. Schlossman, E. Weller, T. Hideshima, C. Mitsiades et al., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma, Blood, vol.100, issue.9, pp.3063-3067, 2002.
DOI : 10.1182/blood-2002-03-0996

P. Richardson, E. Blood, C. Mitsiades, S. Jagannath, S. Zeldenrust et al., A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma, Blood, vol.108, issue.10, pp.3458-3464, 2006.
DOI : 10.1182/blood-2006-04-015909

M. Dimopoulos, C. Chen, A. Spencer, R. Niesvizky, M. Attal et al., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma, Leukemia, vol.23, issue.11, pp.2147-2152, 2009.
DOI : 10.1056/NEJMoa0801479

K. Anderson, Lenalidomide and Thalidomide: Mechanisms of Action???Similarities and Differences, Seminars in Hematology, vol.42, pp.3-8, 2005.
DOI : 10.1053/j.seminhematol.2005.10.001

T. Guglielmelli, S. Bringhen, S. Rrodhe, F. Gay, F. Cavallo et al., Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients, European Journal of Cancer, vol.47, issue.6, pp.814-818, 2011.
DOI : 10.1016/j.ejca.2010.12.026

M. Wang, M. Dimopoulos, C. Chen, M. Cibeira, M. Attal et al., Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure, Blood, vol.112, issue.12, pp.4445-4451, 2008.
DOI : 10.1182/blood-2008-02-141614

B. Durie, J. Harousseau, J. Miguel, J. Bladé, B. Barlogie et al., International uniform response criteria for multiple myeloma, Leukemia, vol.27, issue.9, pp.1467-1473, 2006.
DOI : 10.1038/sj.bmt.1703035

URL : http://www.nature.com/leu/journal/v20/n9/pdf/2404284a.pdf

E. Stadtmauer, D. Weber, R. Niesvizky, A. Belch, M. Prince et al., Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma, European Journal of Haematology, vol.112, issue.6, pp.426-432, 2009.
DOI : 10.1111/j.1600-0609.2009.01257.x

T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. Davies et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, vol.96, pp.2943-2950, 2000.

D. Gupta, S. Treon, Y. Shima, T. Hideshima, K. Podar et al., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications, Leukemia, vol.174, issue.2, pp.1950-1961, 2001.
DOI : 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R

T. Hideshima, D. Chauhan, K. Podar, R. Schlossman, P. Richardson et al., Novel therapies targeting the myeloma cell and its bone marrow microenvironment, Seminars in Oncology, vol.28, issue.6, pp.607-612, 2001.
DOI : 10.1016/S0093-7754(01)90033-8

F. Davies and R. Baz, Lenalidomide mode of action: linking bench and clinical findings, Blood Reviews, vol.24, issue.1, pp.13-19, 2010.
DOI : 10.1016/S0268-960X(10)70004-7